A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients with Allergic Bronchopulmonary Aspergillosis
Latest Information Update: 08 May 2025
At a glance
- Drugs Dupilumab (Primary)
- Indications Allergic bronchopulmonary aspergillosis; Asthma
- Focus Therapeutic Use
- Acronyms LIBERTY-ABPA AIRED
- Sponsors Regeneron Pharmaceuticals
Most Recent Events
- 01 May 2025 According to Regeneron pharmaceuticals media release, data from this study will be presented at the American Thoracic Society (ATS) International Conference 2025 being held from May 18 to 21 in San Francisco, California
- 08 Jun 2024 This study has ben Completed in Poland, According to European Clinical Trials Database record.
- 17 May 2024 This study has ben Completed in Germany, According to European Clinical Trials Database record.